Roche
Roche on target despite European shrinkage
April 12, 2012Sales and Marketing Illumina, Q1 2012, Roche
Roche saw its business grow in the first three months of the year, thanks to strong showings from hepatitis C …
Roche sponsors Twitter-based diabetes community
April 5, 2012Medical Communications Ignite Health, Roche, Twitter, diabetes
Roche is to sponsor a Twitter-based site devoted talk about diabetes, furthering its close links with online commentators. ‘Diabetes Nest’ …
Roche to submit Herceptin successor to regulators
April 2, 2012Research and Development, Sales and Marketing GSK, Herceptin, Roche, Xeloda
Roche has said it will submit its new breast cancer drug trastuzumab for regulatory review in the US and Europe …
GSK settles cancer patent dispute
March 28, 2012Research and Development, Sales and Marketing GSK, Genmab, Roche, ofatumumab, patents
GlaxoSmithKline has settled a long-running patent dispute over its cancer treatment ofatumumab. The US patents, which relate to recombinant antibody …
Roche’s melanoma pill launched in UK
March 14, 2012Sales and Marketing BMS, CDF, NICE, Roche, Yervoy, Zelboraf
Roche’s Zelboraf has been launched in the UK to treat the deadliest form of skin cancer. Zelboraf (vemurafenib) is the …
inVentiv appoints former Quintiles man Mark Archer
March 9, 2012Business Services, Medical Communications, Sales and Marketing Merck, Quintiles, Roche, Sanofi, inVentiv
Pharma consultants inVentiv Health has appointed Mark as its new senior vice president of European operations and development for inVentiv …
Indian CMO will make Roche blockbusters
March 6, 2012Manufacturing and Production Emcure, Herceptin, India, MabThera, Pegasys, Roche
Roche has reportedly signed an agreement with Emcure Pharmaceuticals of India that will see the latter manufacturing its blockbuster drugs …
Roche’s RoActemra beats Humira in arthritis study
March 5, 2012Research and Development, Sales and Marketing Humira, RA, RoActemra, Roche, arthritis
Roche’s rheumatoid arthritis drug RoActemra has beaten Abbott’s Humira in a head-to-head study. The Phase IV trial showed that RoActemra …
European approval for Roche’s Zelboraf
February 20, 2012Sales and Marketing Cancer, Roche, Yervoy, Zelboraf, melanoma
Roche’s skin cancer pill Zelboraf has been given European approval to treat advanced melanoma. Zelboraf (vemurafenib) is now available in …
NICE no for first line Tarceva
February 17, 2012Sales and Marketing CDF, Cancer, NICE, Roche, Tarceva
NICE no for first line Tarceva Watchdog wants more information on Roche’s drug NICE is not recommending Roche’s lung cancer …
NICE cannot recommend breast cancer drugs
February 14, 2012Sales and Marketing GSK, Herceptin, NHS, NICE, Roche, Tyverb
NICE is not recommending GlaxoSmithKline’s Tyverb or Roche’s Herceptin for use in certain breast cancer patients. The watchdog said in …
FDA grants Roche’s pertuzumab priority review
February 10, 2012Sales and Marketing Herceptin, Roche, pertuzumab
The FDA has accepted Roche’s potential breast cancer treatment pertuzumab for appraisal and granted the drug priority review. The proposed …
Roche rounds off year with solid performance
February 3, 2012Sales and Marketing Roche
A strong performance in its diagnostics division was among the factors enabling Roche to deliver a solid set of results …
GMP issues affect Mircera, Xenical production at Roche plant
January 31, 2012Manufacturing and Production GMP, Mircera, Roche, Tamiflu, Xenical
Supply of two Roche products has been disrupted after an active pharmaceutical ingredient (API) production facility in the US was …
Roche’s Erivedge gains FDA approval
January 31, 2012Sales and Marketing Erivedge, FDA, Roche
The FDA has approved Roche’s Erivedge to treat patients with a common form of skin cancer. Erivedge (vismodegib) is now …
Latest content
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
